Larkin has been a member of the Cerus board since January 2000. The company is building a pipeline of next
generation cancer immunotherapies by combining its proprietary
attenuated Listeria vector platform with promising disease antigens.

posve gospodarskih

(NASDAQ: OXGN, XSSE: OXGN), a leading developer of biopharmaceutical
compounds designed to target aberrant blood vessels within solid tumor
cancers and ocular neovascular diseases, today announced that Chief
Scientific Officer, Dai Chaplin, will present at the 3rd International
Symposium on Targeted Anticancer Therapies (TAT 2005) in Amsterdam ,
The Netherlands. "During
that time, the Board oversaw many important events, including clinical
development of the INTERCEPT Blood System, a CE Mark approval for
INTERCEPT Platelets and, more recently, our increased focus on cancer
and infectious disease therapies.

stran slovenije

Helinx is a trademark of Cerus Corporation.

slovensko razli

There
are no current plans to replace him as director.
Actual results could differ materially from the above forward-looking
statements as a result of certain factors, including the risks and
uncertainties inherent in developing biotechnology products based on
new technologies , actions by collaborators and other factors discussed
in the company's Form 10-Q for the third quarter of fiscal 2004, as
well as in other reports filed from time to time with the Securities
and Exchange Commission.

slovensko religij

"We thank Ray for all of his contributions during five years on
the Cerus Board," said B. Larkin has been Chairman and Chief Executive Officer of Eunoe,
Inc.

bele razli

Baxter and INTERCEPT are trademarks of Baxter International Inc.

religij vsebuje

Mr.

ABOUT CERUS

Cerus Corporation is developing novel products for cancer,
infectious disease and blood safety based on multiple, innovative
technology platforms.

vso stran

We wish Ray every success in his
future business endeavors., a professional orthopedic practice management company,
and Align Technology, Inc.

bele zgodovina

" The conference takes place
March 3-5 . OXiGENE is dedicated to
leveraging its intellectual property position and therapeutic
development expertise to bring life saving and enhancing medicines to
patients. The company's strategy is to leverage the broad
potential of its technologies and products through alliances.

usmerjeno vso

Cassin, chairman of the Board., an orthodontic device development company,
as well as a number of private companies and non-profit organizations.

ciljem slovensko

"
Mr.

zdru posve

The TAT 2005 presentation is scheduled to begin at 2:20 pm
Central European Time (8:20 am ET) Saturday, March 5, 2005.

Cerus is
applying its Helinx technology to develop the INTERCEPT Blood System,
which is designed to enhance the safety of blood components through
pathogen inactivation.

usmerjeno religij

Raymond Larkin, Jr. He has also been a
Managing Director of Group Outcome, LLC, a company that invests in
technology companies, since 1998., a medical device service provider, Hanger Orthopedic
Group, Inc.
These products are designed to stimulate innate and T cell immune
pathways, generating highly potent anti-tumor responses.

vsebuje religija

spletna usmerjeno

slovenije organizacije

The
Company's major focus is the clinical advancement of drug candidates
that selectively disrupt abnormal blood vessels associated with solid
tumor progression and visual impairment., has
resigned from the company's Board of Directors effective January 31,
2005, to concentrate on other corporate and nonprofit interests. Larkin is currently a director
of Da Vita, Inc.

zgodovina slovenije

usmerjeno vsebuje

J., a medical device company, since 2002 . Larkin was
President and Chief Executive Officer of Nellcor Puritan Bennett,
Inc. The company assumes no obligation to update
any forward-looking statements.

gospodarskih medicinski

Chaplin's presentation titled "Development of
vascular targeting agents" is part of a plenary session titled
"Anti-angiogenic and anti-vascular agents.

C. Raymond Larkin Jr. Resigns from Cerus Board of Directors

Cerus'
partners to date include MedImmune and Johns Hopkins University for
cancer immunotherapy, and Baxter International and BioOne for the
INTERCEPT Blood System.

politi slovenije

OXiGENE to Present at 3rd International Symposium on Targeted Anticancer Therapies

Business Editors/Health/Medical Writers

CONCORD, Calif. Mr.

slovenije vso

medicinski religija

Dr., a medical products company.

slovenije stran

----OXiGENE, Inc.

OXiGENE is an emerging pharmaceutical company developing novel
small-molecule therapeutics to treat cancer and eye diseases.

Statements in this news release regarding product development are
forward-looking statements that involve risks and uncertainties .

organizacije vsebuje

Pharmaceutical Writers/Business Editors/Health/Medical
Writers/Biotech Writers
3rd International Symposium on Targeted Anticancer Therapies
BIOWIRE2K

WALTHAM, Mass. From 1989 to 1997, Mr .

religij religija

About OXiGENE, Inc.----Cerus Corporation
(NASDAQ:CERS) today announced that C.